The biochemical basis of Hydroxymethylglutaryl-coa reductase inhibitors as neuroprotective agents in aneurysmal subarachnoid hemorrhage

Pharmaceuticals

Volumn 3, Issue 10, 2010, Pages 3186-3199

  Wong, George Kwok Chu ^a   Poon, Wai Sang ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aneurysm; Hydroxymethylglutaryl CoA reductase inhibitors; Neuroprotective agent; Subarachnoid hemorrhage

Indexed keywords

ALTEPLASE; ATORVASTATIN; DISODIUM 2,4 DISULFOPHENYL N TERT BUTYLNITRONE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NEUROPROTECTIVE AGENT; NIMODIPINE; NYX 059; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ABNORMAL DREAMING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN BLOOD FLOW; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION LOSS; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INFORMATION RETRIEVAL; INSOMNIA; LIVER TOXICITY; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PILOT STUDY; REVIEW; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; SUBARACHNOID HEMORRHAGE; VASCULAR ENDOTHELIUM;

EID: 78650103811     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3103186     Document Type: Review

References (76)

1. Macdonald, R.L.; Pluta, R.M.; Zhang, J.H. Cerebral vasospasm after subarachnoid hemorrhage: The emerging revolution. Nat. Clin. Pract. Neurol. 2007, 3, 256-263.
2. Wong G.K.; Ng, R.Y.; Poon, W.S. Aneurysmal subarachnoid hemorrhage. Surg. Pract. 2008, 12, 51-55.
3. Pluta, R.M.; Hansen-Schwartz, J.; Drier, J.: Vajkoczy, P.; Macdonald, R.L.; Nishizawa, S.; Kasuya, H.; Wellman, G.; Keller, E.; Zauner, A.; Dorsch, N.; Clark, J; Ono, S.; Kiris, T.; LeRoux, P.; Zhang, J.H. Cerebral vasospasm following subarachnoid hemorrhage: Time for a new world of thought. Neurol. Res. 2009, 31, 151-158.
4. Wong, G.K.; Wong, R.; Mok, V.C.; Fan, D.S.; Leung, G.; Wong, A.; Chan, A.S.; Zhu, C.X.; Poon, W.S. Clinical study on cognitive dysfunction after spontaneous subarachnoid haemorrhage: Patient profiles and relationship to cholinergic dysfunction. Acta Neurochir. (Wien) 2009, 151, 1601-1607.
5. Weir, B.; Grace, M.; Hansen, J.; Rothberg, C. Time course of vasospasm in man. J. Neurosurg. 1978, 48, 173-178.
6. Pickard, J.D.; Murray, G.D.; Illingworth, R.; Shaw, M.D.; Teasdale, G.M.; Foy, P.M.; Humphrey, P.R.; Lang, D.A.; Nelson, R.; Richard, P. Effect of oral nimodipine on cerebral infraction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. Brit. Med. J. 1989, 11, 636-642.
7. Pluta, R. Delayed cerebral ischemia and nitric oxide: Review, new hypothesis, and proposed treatment. Pharmacol. Ther. 2005, 105, 23-56.
8. Alabadi, J.A.; Salom, J.; Torregrosa, G.; Miranda, F.J.; Jover, T.; Alborch, E. Changes in the cerebrovascular effects of endothelin-1 and nicardipine after experimental subarachnoid hemorrhage. Neurosurgery 1993, 33, 707-714.
9. Nishizawa, S.; Laher, I. Signaling mechanisms in cerebral vasospasm. Trends Cardiovasc. Med. 2005, 15, 24-34.
10. Ishiguro, M.; Wellman, T.L.; Honda, A.; Russell, S.R.; Tranmer, B.I.; Wellman, G.C. Emergence of R-type Ca2+ channel (CaV 2.3) contributes to cerebral artery constriction after subarachnoid hemorrhage. Circ. Res. 2005, 96, 419-426.
11. Kusaka, G.; Ishikawa, M.; Nanda, A.; Granger, D.N.; Zhang, J.H. Signaling pathways for early brain injury after subarachnoid hemorrhage. J. Cereb. Blood Flow Metab. 2004, 24, 916-925.
12. Dreier, J.P.; Major, S.; Manning, A.; Woitzik, J.; Drenckhahn,c.; Steinbrink, J.; Tolias, C.; Oliveira-Ferreira, A.I.; Fabricius, M.; Hartings, J.A.; Vajkoczy, P.; Lauritzen, M.; Dirnagl, U.; Bohner, G.; Strong, A.J.; COSBID study group. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009, 132, 1866-1881.
13. van der Most, P.J.; Dolga, A.M.; Nijholt, I.M.; Luiten, P.G.; Eisel, U.L. Statins: Mechanisms of neuroprotection. Prog. Neurobiol. 2009, 88, 64-75.
14. Bjorkhem, I.; Meaney, S. Brain cholesterol: Long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 806-815.
15. Bjorkhem, I.; Lutjohann, D.; Diczfalusy, U.; Stahle, L.; Ahlborg, G.; Wahren, J. Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 1998, 39, 1594-1600.
16. Saheki, A.; Terasaki, T.; Tamai, I.; Tsuji, A. In vivo and in vitro blood-brain barrier transport of 3- hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 1994, 11, 305-311.
17. Suzuki, H.; Hasegawa, Y.; Kanamaru, K.; Zhang, J.H. Mechanisms of osteopontin-induced stabilization of blood-brain barrier disruption after subarachnoid hemorrhage in rats. Stroke 2010, 41, 1783-1790.
18. Vergouwen, M.D.; de Haan, R.J.; Vermeulen, M.; Roos, Y.B. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systemic review and meta-analysis update. Stroke 2010, 41, e47-e52.
19. Kramer, A.H.; Fletcher, J.J. Statins in the management of patients with aneurysmal subarachnoid hemorrhage: A systemic review and meta-analysis. Neurocritical. Care 2010, 12, 285-296.
20. Tseng, M.Y.; Czosnyka, M.; Richards, H.; Pickard, J.D.; Kirkpatrick, P.J. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: A phase II randomised placebo-controlled trial. Stroke 2005, 36, 1627-1632.
21. Tseng, M.Y.; Hutchison, P.J.; Czosnyka, M.; Richards, H.; Pickard, J.D.; Kirkpatrick, P.J. Effects of acute pravastatin on intensity of rescue therapy, length of inpatient stay and 6-month outcome in patients after subarachnoid haemorrhage. Stroke 2007, 38, 1545-1550.
22. Endres, M.; Laufs, U.; Liao, J.K.; Moskowitz, M.D. Targeting eNOS for stroke protection. Trends Neurosci. 2004, 27, 283-289.
23. Sironi, L.; Cimino, M.; Guerrini, U.; Calvio, A.M.; Lodetti, B.; Asdente, M.; Balduini, W.; Paoletti, R.; Tremoli, E. Treatment with statins after induction of focal ischemia in rats reduced the extent of brain damage. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 322-327.
24. Endres, M.; Laufs, U.; Huang, Z.; Nakamura, P.; Moskowitz, M.A.; Liao, J.K. Stroke protection by 3-hydroxyl-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 1998, 95, 8880-8885.
25. Calabro, P.; Yeh, E.T. The pleotropic effects of statins. Curr. Opin. Cardiol. 2005, 20, 541-546.
26. Rikitake, Y.; Liao, J.K. Rho GTPase, statins, and nitric oxide. Circ. Res. 2005, 97, 1232-1235.
27. Kureishi, Y.; Luo, Z.; Shiojima, I.; Bialik, A.; Fulton, D.; Lefer, D.J.; Sessa, W.C.; Walsh, K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6, 1004-1010.
28. Amarenco, P.; Moskowitz, M.A. The dynamics of statins: From event prevention to neuroprotection. Stroke 2006, 37, 294-296.
29. Hernandez-Perera, O.; Perez-Sala, D; Navarro-Antolin, J.; Sanchez-Pascuala, R.; Hernandez, G.; Diaz, C.; Lamas, S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorstatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthetase in vascular endothelial cells. J. Clin. Invest. 1998, 101, 2711-2719.
30. Morikawa, S.; Takabe, W.; Mataki, C.; Kanke, T.; Itoh, T.; Wada, Y.; Izumi, A.; Saito, Y.; Hamakubo, T.; Kodama, T. The effect of statins in mRNA levels of genes related to inflammation, coagulation, and vascular constriction in human umbilical vein endothelial cells. Atheroscler. Thromb. 2002, 9, 178-183.
31. Tanaka, N.; Katayama, Y.; Katsumata, T.; Otori, T.; Nishiyama, Y. Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneous hypertensive rats. Brain Res. 2007, 1169, 125-132.
32. Gholami, M.R.; Abolhassani, F.; Pasbakhsh, P.; Akbari, M.; Sobhani, A.; Eshraghian, M.R.; Kamalian, N.; Amoli, F.A.; Dehpoor, A.R.; Sohrabi, D. The effects of simvastatin on ischemicreperfusion injury of sciatic nerve in adult rats. Eur. J. Pharmacol. 2008, 590, 111-114.
33. Urban, P.; Pavlikova, M.; Sivonova, M.; Kaplan, P.; Tatarkova, Z.; Kaminska, B.; Lehotsky, J. Molecular analysis of endoplasmic reticulum stress response after global forebrain ischemia/reperfusion in rats: Effect of neuroprotectant simvastatin. Cell Mol. Neurobiol. 2009, 29, 181-192.
34. Huber, R.; Riepe, M.W. Improved posthypoxic recovery in vitro on treatment with drugs used for secondary stroke prevention. Neuropharmacology 2005, 48, 558-565.
35. Kumagai, R.; Oki, C.; Muramatsu, Y.; Kurosaki, R.; Kato, H.; Araki, T. Pitavastatin, a 3-hydroxy- 3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils. J. Neural. Transm. 2004, 111, 1103-1120.
36. Lim, J.H.; Lee, J.C.; Lee, Y.H.; Choi, I.Y.; Oh, Y.K.; Kim, H.S.; Park, J.S.; Kim, W.K. Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J. Neurochem. 2006, 97, 140-150.
37. Bassuk, S.S.; Rifai, N.; Ridker, P.M. High-sensitivity C-reactive protein: Clinical importance. Curr. Probl. Cardiol. 2004, 29, 439-493.
38. Mora, S.; Ridker, P.M. Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (JUPITER)- Can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol. 2006, 97, 33A-41A.
39. Jialal, I.; Stein, D.; Balis, D.; Grundy, S.M.; Adams-Huet, B.; Devaraj, S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103, 1933-1935.
40. Plenge, J.K.; Hernandez, T.L.; Weil, K.M.; Poirer, P.; Grunwald, G.K.; Marcovina, S.M.; Eckel, R.H. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106, 1447-1452.
41. Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M.; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001, 286, 64-70.
42. van Wissen, S.; Trip, M.D.; Smilde, T.J.; de Graaf, J.; Stalenhoef, A.F.; Kastelein, J.J. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002, 165, 361-366.
43. Bonnet, J.; McPherson, R.; Tedgui, A.; Simoneau, D.; Nozza, A.; Martineau, P.; Davignon, J.; CAP investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effect) study. Clin. Ther. 2008, 30, 2298-2313.
44. Keidar, S.; Aviram, M.; Maor, I.; Oiknine, J.; Brook, G. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in marcophages: In vitro and in vivo studies. Br. J. Clin. Pharmac. 1994, 38, 513-519.
45. Weber, C.; Erl, W.; Weber, K.S.; Weber, P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J. Am. Coll. Cardiol. 1997, 30, 1212-1217.
46. Chopp, M.; Zhang, R.L.; Chen, H.; Li, Y.; Jiang, N.; Rusche, J.R. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 1994, 25, 869-876.
47. Kimura, M.; Kurose, I.; Russell, J.; Granger, D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 1521-1526.
48. Lehr, H.A.; Seemuller, J.; Hubner, C.; Menger, M.D.; Messmer, K. Oxidized LDL-induced leukocyte/endothelial interaction in vivo involves the receptor for platelet activating factor. Arterioscler. Thromb. 1993, 13, 1013-1018.
49. Pantoni, L.; Sarti, C.; Inzitari, D. Cytokines and cell adhesion molecules in cerebral ischemia: Experimental bases and therapeutic perspectives. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 503-513.
50. Jung, K.H.; Chu, K.; Jeong, S.W.; Han, S.Y.; Lee, S.T.; Kim, J.Y.; Kim, M.; Roh, J.K. HMGCoA reductase inhibitor, Atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004, 35, 1744-1749.
51. Clarke, R.M.; Lyons, A.; O'Connell, F.; Deighan, B.F.; Barry, C.E.; Anyakoha, N.G.; Nicolaou, A.; Lynch, M.A. A pivotal role for interleukin-4 in Atorvastatin-associated neuroprotection in rat brain. J. Biol. Chem. 2008, 283, 1808-1817.
52. Balduini, W.; Mazzoni, E.; Carloni, S.; de Simoni, M.G.; Perego, C.; Sironi, L.; Cimino, M. Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin 1β and tumor necrosis factor-α mRNA induction, and does not affect endothelial nitric oxide synthase expression. Stroke 2003, 34, 2007-2012.
53. Chan, P.H. Role of oxidants in ischemic brain damage. Stroke 1996, 27, 1124-1129.
54. Vaughan, C.; Delanty, N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999, 30, 1969-1973.
55. Hussein, O.; Schlezinger, S.A.; Rosenblat, M.; Keidar, S.; Aviram, M. Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effects of the drug and its binding to LDL. Atherosclerosis 1997, 128, 11-18.
56. Chen, L.; Haught, W.H.; Yang, B.; Saldeen, T.G.; Parthasarathy, S.; Mehta, J.L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J. Am. Coll. Cardiol. 1997, 30, 569-575.
57. Aviram, M.; Rosenblat, M.; Bisgaier, C.L.; Newton, R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998, 138, 271-280.
58. Humans, J.A.; Ubbink, J.B.; Jerling, J.J.; Delport, R.; Vermaak, W.J.; Vorster, H.H.; Lagendijk, J.; Potgieter, H.C. The effect of simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolemia. Clin. Chem. Acta 1997, 263, 67-77.
59. Giroux, L.M.; Davignon, J.; Naruszewicz, M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived marcophages. Biochem. Biophys. Acta 1993, 1165, 335-338.
60. Wassmann, S.; Laufs, U.; Baumer, A.T.; Muller, K.; Ahlbory, K.; Linz, W.; Rosen, R.; Bohm, M.; Nickenig, G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37, 1450-1457.
61. Westermaier, T.; Stetter, C.; Vince, G.H.; Pham, M.; Tejon, J.P.; Eriskat, J.; Kunze, E.; Matthies, C.; Ernestus, R.I.; Solymosi, L.; Roosen, K. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: A randomized placebo-controlled, clinical study. Crit. Care. Med. 2010, 38, 1284-1290.
62. Huhle, G.; Abletshauser, C.; Mayer, N.; Weidinger, G.; Harenberg, J.; Heene, D.L. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb. Res. 1999, 95, 229-234.
63. Hale, L.P.; Craver, K.T.; Berrier, A.M.; Sheffield, M.V.; Case, L.D.; Owen, J. Combination of fosinopirl and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1643-1646.
64. Laufs, U.; Gertz, K.; Huang, P.; Nickenig, G.; Bohm, M.; Dirnagl, U.; Endres, M. Atorvastatin upregulates type III nitric oxide synthease in thrombocytes, decreases, platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 2000, 31, 2442-2449.
65. Alfon, J.; Royo, T.; Garcia-Moll, X.; Badimon, L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 1812-1817.
66. Zacco, A.; Togo, J.; Spence, K.; Ellis, A.; Lloyd, D.; Furlong, S.; Piser, T. 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 2003, 23, 11104-11111.
67. Bosel, J.; Gandor, F.; Harms, C.; Synowitz, U.; Djoufack, P.C.; Megow, D.; Dirnagi, U.; Hortnagl, H.; Fink, K.B.; Endres, M. Neuroprotective effects of atorvastatin against glutamateinduced excitotoxicity in primary cortical neurons. J. Neurochem. 2005, 92, 1386-1398.
68. Wong, G.K.; Wong, R.; Mok, V.C.; Fan, D.S.; Leung, G.; Wong, A.; Chan, A.S.; Zhu, C.X.; Poon, W.S. Clinical study on cognitive dysfunction after spontaneous subarachnoid haemorrhage: Patient profiles and relationship to cholinergic dysfunction. Acta Neurochir. (Wien). 2009, 151, 1601-1607.
69. Cramer, C.; Haan, M.N.; Galea, S.; Langa, K.M.; Kalbfleisch, J.D. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008, 71, 344-350.
70. Lu, D.; Qu, C.; Goussev, A.; Jiang, H.; Lu, C.; Schallert, T.; Mahmood, A.; Chen, J.; Chopp, M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J. Neurotrauma. 2007, 24, 1132-1146.
71. Gao, C.; Liu, W.; Sun, Z.D.; Zhao, S.G.; Liu, X.Z. Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits capase-dependent apoptosis pathway. BMC Neurosci. 2009, 10, doi:10.1186/1471-2202-10-7.
72. Maples, K.R.; Green, A.R.; Floyd, R.A. Nitrone-related therapeutics: Potential of NXY-059 for the treatment of acute ischemic stroke. CNS Drugs. 2004, 18, 1071-1084.
73. Marshall, J.W.; Cummings, R.M.; Bowes, L.J.; Ridley, R.M.; Green, A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003, 34, 2228-2233.
74. Lees, K.R.; Zivin, J.A.; Ashwood, T.; Davalos, A.; Davis, S.M.; Diener, H.C.; Grotta, J.; Lyden, P.; Shuaib, A.; Hardemark, H.G.; Wasiewski, W.W.; Stroke-Acute Iscehmic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 2006, 354, 588-600.
75. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; Emeribe, U.; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007, 357, 562-571.
76. Diener, H.C.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Shuaib, A.; Ashwood, T.; Wasiewski, W.; Alderfer, V.; Hardemark, H.G.; Rodichok, L.; SAINT I and II Investigators. NXY-059 for the treatment of acute stroke. Pooled analysis of the SAINT I and II trials. Stroke 2008, 39, 1751-1758.